Critically ill patients with cirrhosis and low serum sodium. by Cholongitas, E. et al.
Sequential Therapy for
Helicobacter pylori Infection:
Ethical Considerations
Revisited
To the Editor:
We read with interest the recent
paper comparing 8 and 10 days sequen-
tial therapy with traditional (legacy)
triple therapy in a population of Italian
patients.1 In the discussion, the authors
note our concern about whether it was
‘‘still ethical or not to continue admini-
stration of standard triple therapy
taking into account that it is now less
eﬀective than in the past.’’ The authors
misunderstood our concerns. There have
been numerous trials of legacy triple
therapy in Italy and none has yielded
eradication rates in the acceptable
range (eg,2). By themselves the trials
with known inferior therapies or place-
bos are generally unethical and not
needed as we can use a historical
untreated control, which is known to
estimate 0% eradication.3–6 One prin-
ciple of informed consent is that the
investigators provide all relevant infor-
mation, which might aﬀect a subject’s
willingness to participate in a study.
A known inferior therapy cannot be
described as ‘‘standard’’ or ‘‘approved,’’
and thus would not be an appropriate
‘‘control’’ group to compare investiga-
tional Helicobacter pylori regimens in
Italy. In addition, the investigators, must
share the known inferiority of stan-
dard triple, with the institutional review
board and the patients. Since at least
2004, informed consent would require
informing the patients and the institu-
tional review boards that one of the the-
rapies was known to be clearly inferior
with an average treatment success of
approximately 75% for triple therapy
compared with greater than 90% for
sequential therapy in Italy. In addition,
those who received legacy triple therapy
would have an increased risk of develop-
ing clarithromycin-resistant organisms,
which might prejudice their ability to
be subsequently be cured of their infec-
tion.5,6 No additional information was
gained by including legacy therapy in the
study and doing so only raises ethical
questions. Were the patients and the
institutional review boards properly in-
formed in this study? Were all treatment
failures followed up and H. pylori
eradication conﬁrmed?
The study is also interesting
in that the treatment success was rela-
tively low, only 88% in per protocol
and 86% in intention-to-treat analyses
for the standard 10-day sequential
therapy; eﬃcacy for the 8-day regimen
was 90% and 83% for per protocol
and intention-to-treat results, respec-
tively. The lack of susceptibility testing
precludes testing whether it was be-
cause of increasing resistance. Esome-
prazole was used, which diﬀers from
most other Italian studies. It would be
interesting to know if the source or for-
mulation of the other drugs also diﬀ-
ered from what had been used in the
past.
H. pylori infection, as with any
other infectious disease, should be
judged compared with the expected
outcome (ie, 95% or greater treatment
success).5,7 In Rome, neither 8-day or
10-day sequential therapy seems to be
an optimal choice and a diﬀerent regi-
men should be oﬀered. The quadruple
concomitant therapy containing me-
tronidazole, clarithromycin, amoxicil-
lin, and a proton pump inhibitor may
be a better option.
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Critically Ill Patients With
Cirrhosis and Low Serum
Sodium
To the Editor:
We read with interest the paper
by Jenq CC et al,1 recently published
in Journal of Clinical Gastroentero-
logy, regarding the ability of serum
sodium (Na) to predict the survival
in critically ill cirrhotic patients ad-
mitted to the intensive care unit (ICU).
Particularly, low sodium levels were
associated with higher complications
of cirrhosis, in-hospital mortality, and
poor short-term prognosis. To add to
their evaluation, we report our experi-
ence in 412 patients with cirrhosis
(male: 59.2%, mean age: 49.3±12 y,
alcohol was the main cause of cirrho-
sis), who were consecutively admitted
to the Royal Free Hospital ICU. At
admission, several variables, including
demographic and clinical data, and
laboratory parameters [including full
blood count, lactate, biochemical and
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clotting proﬁle, arterial blood gas, and
inspiratory concentration of oxygen
(FiO2)] had been prospectively col-
lected for each patient. During the
ICU stay, gastrointestinal (G.I.) bleed-
ing episodes, development of aspira-
tion pneumonia and additional use of
inotropes, mechanical ventilation or
hemoﬁltration were also recorded. Li-
ver-speciﬁc prognostic models [Child-
Pugh (CTP) and MELD scores] and
general-ICU models (APACHE II
and SOFA scores) were evaluated on
ICU admission. All data were analyzed
using the statistical package SPSS
(version 13.0). Chi-square test was
used for categorical variables and the
Mann-Whitney U test was used for
quantitative variables in order to com-
pare the patients with hyponatre-
mia (Nar135mmol/L) at admission
versus those without hyponatremia
(Na>135mmol/L). The discrimina-
tive ability of sodium and prognostic
scores at baseline was evaluated by
using the area under a receiver operat-
ing characteristic (ROC) curve (AUC).
The overall mortality in ICU or
6 months after discharge from ICU
was 61.2% mainly owing to multi-
ple organ failure (45.4%), respiratory
failure (18.6%), and renal failure
(11.9%). The patients with hyponatre-
mia (group 1, n=118, 28.6%), com-
pared with those with normal sodium
(group 2, n=294, 71.4%), had sig-
niﬁcantly higher mortality (74% vs.
56%, P<0.001). In addition, group 1
patients, compared with group 2 pa-
tients, were more likely to have G.I.
bleeding (56% vs. 28%, P<0.001),
hepatorenal syndrome (32% vs. 14%,
P<0.001), and severe ascites (30% vs.
21%, P=0.032) at admission to ICU,
and need for cardiovascular support
with inotropes (54% vs. 38%, P=0.006),
mechanical ventilation (92% vs. 78%,
P=0.02) and hemoﬁltration support
(25% vs. 8%, P<0.001). Interest-
ingly, group 1 patients, compared with
group 2 patients, had signiﬁcantly
higher levels of serum bilirubin
(11.2mg/dL vs. 7.8mg/dL, P=0.005),
serum creatinine (2.2mg/dL vs. 1.4
mg/dL, P<0.001), CTP score (11 vs.
10, P=0.041), and lower pH (7.3 vs.
7.6, P<0.001). However, in the multi-
variate analysis, FiO2, serum lactate,
bilirubin and renal dysfunction, but
not hyponatremia, were the indepen-
dent factors of mortality. Moreover,
based on the area under the ROC
curves, the SOFA score had the best
discriminative accuracy for mortality
(AUC=0.84) and hyponatremia the
worst discrimination value (AUC:
0.62). On the basis of these ﬁndings,
we believe that although hyponatremia
may reﬂect advanced cirrhosis and it
has been suggested for incorporation
into the MELD to enhance its prog-
nostic ability,2 further studies are
needed in order to elucidate better its
precise impact on mortality in this
group of critically ill patients.
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Serum Sodium in Critical
Cirrhotic Patients
To the Editor:
We are pleased to have received
the expert opinions from Dr Cholngitas
et al1 from Royal Free Hospital,
London, UK. The role of hyponatremia
in predicting the prognosis of critically
ill cirrhotic patients, the main ﬁnding
of this study, supports the conclusion
of the review article by Gines and
Guevara.2 Hyponatremia in liver cirr-
hosis is the consequence of overactiva-
tion of neuroendocrine systems, which
results from arterial vasodilatation. It
has been considered as a key marker of
prognosis in cirrhosis. The development
of hyponatremia is associated with an
increased risk of developing hepato-
renal syndrome and hepatic encephalo-
pathy.2 Both hepatorenal syndrome
and hepatic encephalopathy are poor
signs in cirrhotic patients. With regard
to diﬀerent results obtained by this
investigation and that of 412 cirrhotic
patients carried out by Cholngitas
et al,3 particularly with regard to the
role of hyponatremia in outcome pre-
diction in cirrhotic patients, we oﬀer
these explanations:
(1) The patient population diﬀers some-
what between the 2 studies. Alcohol
is the main cause of cirrhosis (69.4%)
in patients surveyed by Cholngitas
et al, but accounts for only 21% of
the cases of cirrhosis in our study,
in which the main cause instead was
hepatitis B (41%).
(2) National Health Insurance in
Taiwan did not approve terlipressin
plus albumin in hepatorenal syn-
drome until mid 2005. Thus, most
of the patients in our study did not
receive management for terlipressin
plus albumin. In a sense, the clinical
course of hyponatremia in our pa-
tients was not aﬀected by an eﬀective
treatment, such as vasoconstrictor
plus albumin, association between
hyponatremia and mortality unmo-
diﬁed. We assume that the treatment
of terlipressin plus albumin may
correct the hyponatremia and im-
prove outcomes, and therefore, im-
pacts the capability of serum sodium
level in predicting short-term prog-
nosis of cirrhotic patients.
Finally, given the limitations
of this study,4 we agree that, as men-
tioned by Dr Cholngitas et al, further
studies are required to better eluci-
date its precise impact on mortality
in this group of critically ill patients,
especially in the era of vasoconstrictor
treatment.
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